Literature DB >> 22888997

Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology.

Alan Hb Wu1, Roy Gerona, Patil Armenian, Deborah French, Matthew Petrie, Kara L Lynch.   

Abstract

BACKGROUND: Gas chromatography (GC) and liquid chromatography (LC) coupled with mass spectrometry (MS) are widely used to confirm drug screening results and for urine screening in presumed intoxicated patients. These techniques are better suited to targeted analysis than to general unknown screening and, due to the complexity of testing, results are seldom available rapidly enough to contribute to the immediate care of the patient. High resolution (HR)/MS with time-of-flight (TOF) or orbitrap instruments offer potential advantages in clinical toxicology. COMPARISON OF GC-MS, LC-MS/MS AND LC-HR/MS: For unknown analyses, GC-MS and LC-MS/MS require comparison of full-scan spectra against preestablished libraries. Operation in full-scan mode greatly reduces sensitivity and some drugs present in low but significant concentrations may be missed. Selected ion monitoring (SIM) in GC/MS and selected reaction monitoring (SRM) in LC-MS/MS, where only targeted ions are monitored, increase sensitivity but require prior knowledge of what compound is to be measured. LC-HR/MS offers mass assignment with an accuracy of 0.001 atomic mass units (amu) compared with 1 amu in conventional MS. Tentative identification is thus directed to a very limited set of compounds (or even one unique compound) based on the exact molecular formula rather than a fragmentation pattern, since HR/MS can discriminate between compounds with the same nominal molecular mass. LC-MS/MS has clear advantages over GC/MS in ease and speed of sample preparation and the opportunities for its automation. LC-HR/MS is more suitable to clinical toxicology because the drugs present in a sample are rarely known a priori, and tentative identifications of unknowns can be made without the availability of a reference standard or a library spectrum. Blood can be used in preference to urine which is more relevant to the patient's current clinical situation.
METHODS: A literature search was conducted using PUBMED for clinical toxicology, adulterants in illicit drugs and herbal supplements, and case reports using LC-TOF/MS and LC-HR/MS. Only 42 papers in English were identified in these searches. LC-HR/MS IN CLINICAL TOXICOLOGY: LC-HR/MS has been used to detect designer drugs, doping agents, (neurosteroids) and adulterants such as levamisole, a veterinary antihelmitic found in street cocaine, and pharmaceuticals in herbal medications marketed to contain only natural ingredients. LC-HR/MS has proved useful for cases where existing tests were unable to identify the cause of the intoxication. One patient suffered a drug-induced seizure which was originally thought to be caused by an herbal medication, but diphenhydramine was determined to be the culprit. In another, 5-oxoproline was identified as the cause of metabolic acidosis seen in chronic acetaminophen (paracetamol) use. LC-HR/MS has successfully identified medications that were mislabeled or misrepresented street drugs. In one case, medications sold as diazepam were determined to be glyburide instead. The identification of novel designer amines, stimulants found in "bath salts", and synthetic cannabinoids are well suited to LC-HR/MS. Dozens or even hundreds of possible compounds cannot realistically be tested on an individual basis by targeted LC-MS/MS or GC/MS analysis.
CONCLUSIONS: LC-HR/MS offers unique opportunities for time-sensitive clinical analysis of blood samples from intoxicated patients and for comprehensive screening in a wide range of situations and materials. While the identification is not as definitive as that obtained by conventional fragmentation MS, the presumptive identification can be confirmed later with standards and spectral library matches. Optimum utilization of the presumptive diagnosis requires close collaboration between the laboratory analysts and their clinical counterparts.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22888997     DOI: 10.3109/15563650.2012.713108

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  20 in total

1.  Separation and Detection of Trace Fentanyl from Complex Mixtures Using Gradient Elution Moving Boundary Electrophoresis.

Authors:  Shannon T Krauss; David Ross; Thomas P Forbes
Journal:  Anal Chem       Date:  2019-09-27       Impact factor: 6.986

Review 2.  Quantitative mass spectrometry methods for pharmaceutical analysis.

Authors:  Glenn Loos; Ann Van Schepdael; Deirdre Cabooter
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2016-10-28       Impact factor: 4.226

3.  Using Sesame Seed Oil to Preserve and Preconcentrate Cannabinoids for Paper Spray Mass Spectrometry.

Authors:  Brandon Bills; Nicholas Manicke
Journal:  J Am Soc Mass Spectrom       Date:  2020-01-27       Impact factor: 3.109

4.  Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2013-12-30       Impact factor: 4.759

Review 5.  Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication.

Authors:  Katharina Elisabeth Grafinger; Matthias E Liechti; Evangelia Liakoni
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

6.  Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.

Authors:  Matthew D Krasowski; Sean Ekins
Journal:  J Cheminform       Date:  2014-05-10       Impact factor: 5.514

Review 7.  Applications of Fourier Transform Ion Cyclotron Resonance (FT-ICR) and Orbitrap Based High Resolution Mass Spectrometry in Metabolomics and Lipidomics.

Authors:  Manoj Ghaste; Robert Mistrik; Vladimir Shulaev
Journal:  Int J Mol Sci       Date:  2016-05-25       Impact factor: 5.923

8.  Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs.

Authors:  Hari Nair; Fred Woo; Andrew N Hoofnagle; Geoffrey S Baird
Journal:  J Toxicol       Date:  2013-07-10

9.  An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA.

Authors:  Joseph A Tyndall; Roy Gerona; Giuliano De Portu; Jordan Trecki; Marie-Carmelle Elie; Judith Lucas; John Slish; Kenneth Rand; Lindsay Bazydlo; Martina Holder; Matthew F Ryan; Paul Myers; Nicole Iovine; Michelle Plourde; Emily Weeks; James R Hanley; Greg Endres; Danielle St Germaine; Paul J Dobrowolski; Michael Schwartz
Journal:  Clin Toxicol (Phila)       Date:  2015-11-10       Impact factor: 3.738

10.  Use of a data warehouse at an academic medical center for clinical pathology quality improvement, education, and research.

Authors:  Matthew D Krasowski; Andy Schriever; Gagan Mathur; John L Blau; Stephanie L Stauffer; Bradley A Ford
Journal:  J Pathol Inform       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.